<DOC>
	<DOC>NCT00390091</DOC>
	<brief_summary>The primary purpose of this study is to assess the safety and pharmacodynamic effect of LJP 394 at doses of 100 mg, 300 mg and 900 mg on anti-dsDNA antibody levels in patients with SLE.</brief_summary>
	<brief_title>Study of LJP 394 (Abetimus Sodium) in Lupus Patients</brief_title>
	<detailed_description>STUDY NOW INCORPORATED INTO PHASE 3 STUDY NCT00089804.</detailed_description>
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>Males or females between 12 and 70 years old. Diagnosis of Systemic Lupus Erythematosus (SLE) Females must be nonpregnant and nonlactating. Females must agree to use adequate birth control methods during the course of the study. Ability to have weekly intravenous (IV) administration of study drug. Prior exposure to abetimus sodium within 6 months prior to screening. Patients not on stable medications for 30 days prior to screening. Patients with acute or chronic infections.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Lupus</keyword>
	<keyword>Nephritis</keyword>
	<keyword>Kidney</keyword>
	<keyword>SLE</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Nephritis, Lupus</keyword>
</DOC>